Cart
sales@molnova.com
CCF0058981
CAS No. 2708934-53-4
CCF0058981( —— )
Catalog No. M28541 CAS No. 2708934-53-4
CCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 52 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 324 | In Stock |
|
| 50MG | 439 | In Stock |
|
| 100MG | 551 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCF0058981
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.
-
DescriptionCCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.
-
In VitroCCF0058981 (CCF981) has cytopathic effect (CPE) inhibition (EC50=497 nM) and plaque reduction (EC50=558 nM) in vitro viral replication. CCF0058981 has the 50% cytotoxic concentration (CC50) in the CPE antiviral assay of >50 μM. CCF0058981 has a T1/2 of 21.1 min, a CLlnt of 141 mL/min?kg in Human liver microsomes.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorNF-κB|NOS|ROS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2708934-53-4
-
Formula Weight442.9
-
Molecular FormulaC24H19ClN6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (56.45 mM)
-
SMILESO=C(N(C=1C=CC(=CC1)C2=CN=CN2)CC=3C=CC=C(Cl)C3)CN4N=NC=5C=CC=CC54
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.C Li, et al.Compounds from the bark of Illicium tsaii and their anti-inflammatory activity. Planta Medica. 2014 July; 80.
molnova catalog
related products
-
ML-180
ML-180 is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist (IC50 of 3.7 μM) .ML-180 (0.5-5 μM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells[2]. ML-180 (5 μM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling.
-
(Tyr0)-pTH-Related P...
(Tyr0)-pTH-Related Protein (1-34) (human, mouse, rat)
-
GSK329
GSK329 is an effective and selective inhibitor of TNNI3 Interacting Kinase (TNNI3K). GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury.
